Jump to Navigation
Home

Main menu

  • Home
  • Latest Stories
  • Markets Map
  • Trends and Sentiments
  • Leading Topics
  • News Search
  • Comments and Analysis

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • About Us
  • Liam Payne Hops On The Bilingual Bandwagon With J Balvin-...
  • Daily Insider Ratings Round Up 4/18/18: APO, CERC, HCAP
  • Skechers USA's (SKX) Management on Q1 2018 Results...
  • Now See Wall Street's 38 'Safer'...
  • When Criminal Justice and Environmental Justice Collide
  • Shire rejects $63 billion Takeda bid as Allergan drops...
  • JPMorgan, National Bank of Canada, others test debt...
  • UFC Fight Night 128 Ceremonial Weigh-In Video Live Stream...
  • Here's A Social Impact Campaign NOT To Emulate This...
  • Ariana Grande Returns To Pop With New Single 'No...

    Complete Genomics Well Positioned To Move From Research To Clinical In Genome Sequencing

    Thu, 04/19/2012 - 03:58 EDT - Seeking Alpha
    • GNOM
    • OneMedPlace

    By OneMedPlace:
    By Herina Ayot
    Complete Genomics (GNOM) is a whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing service. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with advanced informatics and data management software. OneMedRadio recently conducted an interview with Dr. Clifford A. Reid, the company’s President, Chief Executive Officer and Chairman since July 2005. Brett Johnson: Welcome. This is Brett Johnson in New York with OneMed Radio. Today, we are with Dr. Cliff Reid who is the co-founder and CEO of Complete Genomics. It’s traded on the NASDAQ under the symbol GNOM. The company is based in Mountain View, California and is in the human genome sequencing business. Thanks for joining us today, Cliff. Dr. Cliff Reid: Good morning, Brett. Good to be here. BJ: So in simple terms, what is human genome sequencing and what is theComplete Story »

    • Original article
    • Login to post comments
     

    Related

    • Complete Genomics: A Leader In DNA Sequencing

      By EXPstocktrader:Company BackgroundComplete Genomics (GNOM) was founded in 2005 and is headquartered in Mountain View, CA. It is an up and coming life sciences company that develops and commercializes an innovative DNA sequencing platform for complete human genome sequencing and analysis.

    • Successful IPOs in Genomics Could Ignite Biotech Stocks

      Rod Raynovich submits:The IPO market is setting up for continued investor interest in the biotech sector.

    • Illumina Takes the Lead in Human Genome Project

      Prohost Biotech submits:In June 2009, Illumina (ILMN) announced the launch of its individual genome sequencing service. The service is built around physician-patient consultation, with a physician’s order required to initiate the process.

    • Complete Genomics: Say No To Sale

      By Medhanie:We knew the likelihood of Complete Genomics (GNOM) remaining an independent company was low. Given its low trading price, difficulty in gaining access to capital and its pending lawsuit with Illumina (ILMN), a sale almost seems inevitable.

    • Today's IPO Market: Interview With Keating Capital

      By OneMedPlace: By Herina Ayot Keating Capital’s President Timothy Keating was interviewed by OneMedRadio where he describes the liquidity premium that gives public companies 3x valuation over private company peers and the dramatic decline in IPOs and increase in size that is debilitating economic growth.Click to hear audio and see below for a full transcript.

    • Rosetta Genomics: The Leader In MicroRNA-Based Molecular Diagnostics

      By Grant Zeng: Rosetta Genomics (ROSG) is an Israel-based molecular diagnostic company focused on developing and commercializing molecular diagnostics for cancers.

    • VASCO Data Security International, Inc. (VDSI) CEO Discusses Q2 2013 Results - Earnings Call Transcript

      VASCO Data Security International, Inc. (VDSI) Q2 2013 Earnings Conference Call July 25, 2013, 10:00 AM ET Executives Kendall Hunt - Founder, Chairman and Chief Executive Officer Jan Valcke - President and Chief Operating Officer Clifford Bown - Executive Vice President and Chief Financial Officer Jochem Binst - Director, Corporate Communications Analysts

    • Rosetta Genomics' CEO Hosts Business Update Conference (Transcript)

      Rosetta Genomics Ltd. (ROSG) Business Update Conference Call October 2, 2012 10:00 a.m. ET Executives Kenneth Berlin - President and Chief Executive Officer Ron Kalfus - Chief Financial Officer Anne Marie Fields - Investor Relations, LHA Presentation Operator

    • Complete Genomics' IPO Meets With Lukewarm Reception

      The Burrill Report submits: By Marie DaghlianDNA sequencing firm Complete Genomics (GNOM) went public after scaling back its deal price more than 30 percent to get it done. Shares began trading on the Nasdaq Global Market on Thursday under the symbol GNOM. The stock closed at $8.03, down more than 10 percent on the first day of trading with volume of nearly 2.5 million shares.

    • Johnson Controls' CEO Discusses Q2 2011 Results - Earnings Call Transcript

      Johnson Controls (JCI) Q2 2011 Earnings Call April 25, 2011 11:00 am ET Executives Glen Ponczak - Director of IR R. McDonald - Chief Financial Officer and Executive Vice President Stephen Roell - Chairman of the Board, Chief Executive Officer, President and Chairman of Executive Committee Analysts Michael Cox - Piper Jaffray Companies David Leiker - Robert W. Baird & Co. Incorporated

    Latest

    Trump went into extraordinary detail on his pitch to put reporters in jail over leaks
    Trump went into extraordinary detail on his pitch...
    The Road To 2025 (Part 2) – Russia And China Have Had Enough
    The Road To 2025 (Part 2) – Russia And China Have...

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 2579.37 0.16% FTSE: 7487.96 -0.07% Nikk.: 22420.08 1.82% DAX: 13465.51 1.75% HSI: 28594.06 1.22% FX: EUR/GBP: 1.1401 USD/EUR: 1.1618 JPY/USD: 114.1510 Commodities: Gold: 1276.1000

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • About Us